By: Ana Gomez

Polypeptide Therapeutic Solutions and PMC Isochem sign business and technology collaboration agreement in the field of Cosmetic and Therapeutic Polypeptide
13/03/2018

12 March 2018- Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services…

Read More
Aura Biosciences Completes $30 Million Series C Financing
26/12/2017

CAMBRIDGE. 21 December 2017– Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer…

Read More
Aura Biosciences announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma
14/11/2017

Light-activated viral nanoparticle for treatment of choroidal melanoma meets early study endpoints NEW ORLEANS. USA. 12 November 2017— Choroidal melanoma has... Read More
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting
26/10/2017

Aura Biosciences announced a late-breaking session in AAO 2017 to highlight Phase 1b Clinical Safety Study for the treatment of primary... Read More
Biomimetic motivates the Open Innovation in the dermatology sector
24/10/2017

BIOMIMETIC organize a coworking workday with customers, contributors and the industrial sector, with the participation of international experts in the field... Read More
AskBio and Columbus Venture Partners launch Gene Therapy Company Viralgen
19/10/2017

New vector core facility will be located in San Sebastián, Spain USA, CHAPEL HILL, October 17, 2017 - Asklepios BioPharmaceutical, Inc.... Read More
Vivet Therapeutics named as one of the “Fierce 15” Biothec Companies of 2017 by FierceBiothec
03/10/2017

Vivet Therapeutics is the only European Company that has been chosen as one of the “Fierce 15”, the final fifteen companies... Read More
The Basque Country receive a unique gene therapy production center in Europe
25/09/2017

The investment fund Columbus Venture Partners and the American company Asklepios Biopharmaceutical merge in the joint venture "Viralgen Vector Core" to... Read More